Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioMerieuxFRA:EYWN +0.75%87 EV-to-OCF is 9.21 as of Aug. 13, 2026, which is 60% below its 10-year median of 22.90. GuruFocus rates FRA:EYWN with a GF Score™ of 87/100 and a GF Value™ of €108.68 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, BioMerieux ranks worse than 56.34% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BioMerieux's Enterprise Value is €8,364 Mil.
BioMerieux's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €908 Mil. Therefore, BioMerieux's EV-to-OCF for today is 9.21.
The historical rank and industry rank for BioMerieux's EV-to-OCF or its related term are showing as below:
FRA:EYWN'
s EV-to-OCF Range Over the Past 10 Years
Min: 9.21 Med: 22.9 Max: 41.91
Current: 9.21
During the past 13 years, the highest EV-to-OCF of BioMerieux was 41.91. The lowest was 9.21. And the median was 22.90.
FRA:EYWN's EV-to-OCF is ranked worse than 56.34% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.2
vs FRA:EYWN: 9.21
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioMerieux's share price for today is €73.45.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioMerieux's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €3.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioMerieux EV-to-OCF Related Terms
BioMerieux EV-to-OCF Historical Data
* Premium members only.
The historical data trend for BioMerieux's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BioMerieux's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMerieux EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BioMerieux's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BioMerieux's EV-to-OCF falls into.
BioMerieux's current Enterprise Value is €8,364 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioMerieux's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €908 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMerieux (FRA:EYWN) has a EV-to-OCF of 9.21 as of Aug. 13, 2026. This is 60% below median its historical median of 22.90. Over the past decade, BioMerieux's EV-to-OCF has ranged from 9.21 to 41.91. According to the industry distribution chart, BioMerieux ranks #120 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 56.3%.
Is BioMerieux's EV-to-OCF too high?
BioMerieux's current EV-to-OCF of 9.21 is 60% below median its 10-year median of 22.90. Over the past 10 years, this metric has ranged from a low of 9.21 to a high of 41.91. The Medical Diagnostics & Research industry median EV-to-OCF is 6.20. BioMerieux's value of 9.21 is 48.5% above this industry median. Based on the distribution chart, BioMerieux ranks #120 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, BioMerieux has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMerieux's EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BioMerieux ranks #120 out of 213 companies for EV-to-OCF. This places BioMerieux in the lower half of its industry. The industry median EV-to-OCF is 6.20. BioMerieux's value of 9.21 is 48.5% above this benchmark. Historically, BioMerieux's own EV-to-OCF has ranged from 9.21 to 41.91 over the past decade. While the company's 10-year median is 22.90 vs. the industry median of 6.20, BioMerieux has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.20, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioMerieux's current EV-to-OCF of 9.21 is 48.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioMerieux's current EV-to-OCF is 9.21, which is 60% below median its own 10-year median of 22.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMerieux stock overvalued right now?
Based on GuruFocus' analysis, BioMerieux (FRA:EYWN) is currently considered Significantly Undervalued. The stock's GF Value™ is €108.68, compared to a current price of €73.45 — trading 32.4% below its estimated fair value. The current EV-to-OCF is 9.21, which is 60% below median its 10-year median of 22.90 and 48.5% above the Medical Diagnostics & Research industry median of 6.20. BioMerieux's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BioMerieux (FRA:EYWN), the current EV-to-OCF is 9.21 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMerieux (FRA:EYWN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued.
The current stock price of €73.45 is trading 32.4% below its estimated GF Value™ of €108.68.
GuruFocus considers BioMerieux to be Significantly Undervalued.
Key valuation signals for FRA:EYWN:
EV-to-OCF: 9.21 (60% below median its 10-year median of 22.90)
GF Value™: €108.68 vs. price of €73.45 (32.4% below fair value)
Industry Position: 48.5% above the Medical Diagnostics & Research median (#120 of 213)
No single metric tells the full story. See the FRA:EYWN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
87GF Score
Get the complete analysis for FRA:EYWN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EYWN has been successfully added to your 
